Explore a comprehensive report of diagnostic experiences and the current landscape of genetic testing, compiled from the perspectives of healthcare providers in 30 countries.
“Lack of insurance coverage as financial support for testing remains our biggest challenge.”
“Limited access to specialists in rare disease diagnosis complicates the diagnostic process.”
“In the U.S., we primarily utilize Microarray and Whole Exome Sequencing (WES) when diagnosing suspected rare diseases.”